Sunrest Lifescience Ltd. இன் கணக்கு குறிப்புகள்

Mar 31, 2025

Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity shares having par value of INR 10 per share. Accordingly, all equity shares rank equally with regard to dividends and share in the Company''s residual assets. The equity shares are entitled to receive dividend as declared from time to time after to payment of dividend to preference shareholders. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

Details of shares issued for consideration other than cash:-

Note 1:During thefinancial year 2022-2023, the Company had issued bonus shares without any cosnideration by capitlizing its reserves during the year. The Company has alloted 9,90,000 equity shares of f 10 each fully paid up by way of bonus shares to the exisiting share-holders in the ratio of 99:1 i.e. 99 shares for each 1 equity share fully paid up held by the existing share-holders.

Note 2 :During the financial year 2022-23, the Company had issued bonus shares without any cosnideration by capitlizing its reserves during the year. The Company has alloted 20,00,000 equity shares of f 10 each fully paid up by way of bonus shares to the exisiting share-holders in the ratio of 2:1 i.e. 2 shares for each 1 equity share fully paid up held by the existing share-holders.

Details of shares issued for consideration other than cash:-

Note 1:During thefinancial year 2022-2023, the Company had issued bonus shares without any cosnideration by capitlizing its reserves during the year. The Company has alloted 9,90,000 equity shares of f 10 each fully paid up by way of bonus shares to the exisiting share-holders in the ratio of 99:1 i.e. 99 shares for each 1 equity share fully paid up held by the existing share-holders.

Note 2 :During the financial year 2022-23, the Company had issued bonus shares without any cosnideration by capitlizing its reserves during the year. The Company has alloted 20,00,000 equity shares of f 10 each fully paid up by way of bonus shares to the exisiting share-holders in the ratio of 2:1 i.e. 2 shares for each 1 equity share fully paid up held by the existing share-holders.

*Terms and Conditions of Loan from Indian Overseas Bank Limited

The loan from Indian Overseas Bank Limited is for the motor vehicle in the name of the Director and carries rate of interest of 7.30% pa. The loan is repayable in 36 monthly installments of INR 121577 each staring from 10th March 2022. The motor vehicle and loan are both in the name of the Director

@Terms and conditions of Loan from ICICI Bank Limited

The Term loan with ICICI Bank Limited for the purchase of immoveable property is secured against the property of the Company situated at Westgate D Block Office number 608, Ahmedabad at carries a floating rate of interest which at present is 6.5% plus 3% spread i.e. 9.5%. The loan is repayable in 180 months with EMI of INR

114,865

^ATerms and conditions of Loan from The Kalupur Commercial Co-operative Bank Limited

The loan from Kalupur Commercial Co-operative Bank limited is for the motor vehicle in the name of the Director and carries rate of interest of 8.30% pa. The loan is repayable in 72 monthly installments of INR 39,600 each staring from 31 Dec 2024. The motor vehicle and loan are both in the name of the Director

# Terms and conditions of loan from Directors & relatives

The loan from the directors and relatives are interest free and there is no predecided maturity for re-payment.

The Company operates in only one business segment which trading of goods of pharmaceuticals majorly and hence the dislcosure in terms of AS-17 is not furnished.

The Company has not made provision for the retirement benefits for the employees as mandated under AS-15

During the previous year, the Company has raised funds by issuing equity shares through IPO. The Company has issued 12,91,200 equity shares of Rs. 10 each and has raised Rs. 10,84,60,800/- (including securities premium) by way of making a public issue on the EMERGE platform of NSE

The provisions of Corporate social responsibility are not applicable to the Company and hence, the details for the same are not reported

Previous year figures are regrouped wherever necessary.

The financial statements are approved by the Board of Directors on 30th May 2025

6.0 Additional disclosures

Details of crypto currency or virtual currency

(a) The Company has neither traded nor invested in Crypto currency or Virtual Currency during the for the period year ended 31st March 2025 Further, the Company has also not received any deposits or advances from any person for the purpose of trading or investing in Crypto Currency or Virtual Currency.

(b) The Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government authority.

Undisclosed income

( ) During the Period, the Company has not surrendered or disclosed as income any transactions not recorded in the books

of accounts in the course of tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(d) Relationship with struck off companies

The Company does not have any transactions with the companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 for the financial year ended on 31st March 2025

(e) Compliance with numbers of layers of companies

The Company is in compliance with the number of layers of companies in accordance with clause 87 of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017 for the financial years ended on 31st March 2025

Utilisation of borrowed funds and share premium

During the financial years ended on 31st March 2025, the Company has not advanced or loaned or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or

(f) ii) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

For financial years ended on 31st March 2025, the Company has not received any fund from

any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

ii) provide any guarantee, security, or the like on behalf of the ultimate beneficiaries.

As informed to us no proceeding have been initiated nor pending against the company for holding any benami property ¹⁶ under the Benami Transactions (Prohibition) Act,1988 (45 of 1988) and rules made thereunder.

(h) The original deeds of the immoveable property owned by the Company are mortgaged with the ICICI Bank Limited and

are in the name of the Company. This mortgage is towards the acquisition of the said immoveable property.

7.0 Contingent Liabilities	Amount in lakhs unless specified otherwise
Particulars	31-03-2025	31-03-2024
1) Corporate guarantee given for loan borrowed by Trilend Pharmaceuticals Private Limited	(Refer Note below)	(Refer Note below)
2) Claims against the Company not acknowledged as debt i.e. Income tax demand	01.50	01.50
3) Claims against the Company not acknowledged as debt i.e. Income tax demand	0.04	0.04

Note for contingent liability

The Company has issued an unconditional & irrevocable corporate guarantee for working capital loan being Term Loan & Overdraft facility borrowed by Trilend Pharmaceuticals Private Limited for a sum of INR 37 lakhs. In the event Trilend Pharmaceuticals Private Limited doesn''t repay the loan, the Company would be liable to make the payments of loan along with applicable interest and outstanding amount